|
Çѱ¹MSD À¯ÇÑȸ»ç |
Çѱ¹MSD CRA ´Ù¼ö ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
09.04 |
|
|
ºê·¹ÀÎÇãºê |
[ÇìµåÇåÆÃ]±Û·Î¹ú ¸ÞµðÄà Áø´ÜÀåºñ ȸ»ç-ÀÓ»ó °æ·ÂÀÚ Ã¤¿ë
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
09.23 |
|
|
ÆĹ̼¿(ÁÖ) |
ÆĹ̼¿(ÁÖ) ÀÓ»óÆÀ °æ·ÂÁ÷ ä¿ë°ø°í
°æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
01.19 |
|
|
PPD Development Pte. Ltd. |
SCRA ¹× CRA II ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
06.07 |
|
|
InnoHR |
±Û·Î¹ú Á¦¾à»ç CRA 2³â ÀÌ»ó
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.18 |
|
|
(ÁÖ)Ƽ¾Ø¾Ë¹ÙÀÌ¿ÀÆÕ |
RA ÀÇ·á±â±â ÀÓ»ó ´ã´çÀÚ ¸ðÁý
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.29 |
|
|
(ÁÖ)½Ã¹ÍÄÚ¸®¾Æ |
(ÁÖ)½Ã¹ÍÄÚ¸®¾Æ CRA I, II, Sr. °æ·ÂÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
11.28 |
|
|
À̳뿡ÀÌÄ¡¾ËÄÁ¼³Æà |
[¿Ü±¹°èÁ¦¾àȸ»ç] CRA ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
06.15 |
|
|
¿¡À̽ºÆÄÆ®³Ê½º |
±¹³» Á¦¾àȸ»ç Sr.CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
02.18 |
|
|
ICON Clinical Research Korea |
Jr. Clinical Research Associate(Oncology)
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
¿¡À̽ºÆÄÆ®³Ê½º |
¿Ü±¹°è Á¦¾àȸ»ç Sr.CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
02.18 |
|
|
(ÁÖ)Äɾî»çÀ̵å |
[Á¦¾à/¹ÙÀÌ¿À] ¼öÀÇÀÓ»óÀǾ࿬±¸¼Ò Áø´Ü°Ë»ç/ÀÓ»ó½ÃÇè ¿¬±¸
°æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
11.17 |
|
|
¿¡À̽ºÆÄÆ®³Ê½º |
±¹³» ´ëÇü CRO CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
02.18 |
|
|
ICON Clinical Research Korea |
Study Start-up Associate
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] °æ·ÂCRA ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
08.03 |
|